TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15542162

Group type: EXPERIMENTAL
Intervention: Aqueous cream
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Sucralfate cream
Number of subjects: 357

Group type: COMPARATOR
Intervention: No cream (control)
Number of subjects: 357
Study: 11380297

Group type: EXPERIMENTAL
Intervention: hCG three times (group I)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: hCG on the day of embryo transfer + daily vaginal progesterone (group II)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone only (group III)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: hCG in combination with daily vaginal progesterone (group IV)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Progesterone only (group V)
Number of subjects: 413

Group type: COMPARATOR
Intervention: hCG only or additional injection of hCG
Number of subjects: 413
Study: 9233866

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin (3.6 mg subcutaneously every four weeks for three years)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 415
Study: 7654898

Group type: EXPERIMENTAL
Intervention: Pravastatin (20-40 mg) with hypolipemiant dietetic treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (dietetic treatment only)
Number of subjects: 16
Study: 3300232

Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30115007

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia with BIS monitoring and warming
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-desflurane anesthesia (control group)
Number of subjects: 70
Study: 26945818

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.257% w/v
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ropivacaine 40 ml
Number of subjects: 51
Study: 25181766

Group type: EXPERIMENTAL
Intervention: Telephone reinforcement (TR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negotiated maintenance contract without TR
Number of subjects: 0
Study: 22294813

Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (healthy controls matched for age, sex, and BMI)
Number of subjects: 34
Study: 21087499

Group type: EXPERIMENTAL
Intervention: Propranolol added to standard treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 44
Study: 19125710

Group type: EXPERIMENTAL
Intervention: Reversed saphenous venous bypass
Number of subjects: 121

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene/dacron bypass
Number of subjects: 121
Study: 15908318

Group type: EXPERIMENTAL
Intervention: Pegasys
Number of subjects: 197

Group type: COMPARATOR
Intervention: Roferon-A
Number of subjects: 197
Study: 14501856

Group type: EXPERIMENTAL
Intervention: Intraoperative Thymoglobulin (1 mg/kg/dose, 3 to 6 doses during the first week posttransplant)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Postoperative Thymoglobulin (1 mg/kg/dose, 3 to 6 doses during the first week posttransplant)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intraoperative Thymoglobulin
Number of subjects: 58
Study: 10434160

Group type: EXPERIMENTAL
Intervention: Venlafaxine (200 to 300 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Paroxetine (30 to 40 mg/day)
Number of subjects: 123
Study: 8794438

Group type: EXPERIMENTAL
Intervention: E3 (0.5 mg every other day) + Ca (0.5 g/day)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: E3 + Ca + sCT (50 IU x 2/day)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: sCT + Ca
Number of subjects: 214

Group type: COMPARATOR
Intervention: Ca
Number of subjects: 214
Study: 1806878

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6352626

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g iv dose
Number of subjects: 29
Study: 31157663

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4612

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4612
Study: 30486799

Group type: EXPERIMENTAL
Intervention: Adult Mental Health Practice Support Program (AMHPSP) training for family physicians
Number of subjects: 129

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 129
Study: 26037521

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 μg/d)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 24675102

Group type: COMPARATOR
Intervention: Parenteral corticosteroid (PS) (n=33)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 4 mg nebulized steroid (NB) (n=27)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 8 mg nebulized steroid (NB) (n=26)
Number of subjects: 86
Study: 22090186

Group type: EXPERIMENTAL
Intervention: High maternal expressed emotion (EE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High child expressed emotion (EE) regarding fathers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High child and maternal expressed emotion (EE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High child expressed emotion (EE) regarding parents
Number of subjects: 0
Study: 20932869

Group type: EXPERIMENTAL
Intervention: Casopitant
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study: 17919549

Group type: EXPERIMENTAL
Intervention: Goserelin acetate 10.8 mg plus iron (ferrous sulfate 325 mg TID)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham (iron monotherapy)
Number of subjects: 110
Study: 15902631

Group type: EXPERIMENTAL
Intervention: Mammography (Mx)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 613
Study: 12074599

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (250 mg/day for six weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (LOC subjects before supplementation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (HIC subjects)
Number of subjects: 40
Study: 10335420

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg for weeks 1 and 2, 30 mg for weeks 3 and 4, twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study: 7497554

Group type: EXPERIMENTAL
Intervention: Lateral popliteal sciatic nerve block (Group PS, n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ankle block (Group AB, n = 19)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral popliteal sciatic nerve block (Group PS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ankle block (Group AB)
Number of subjects: 40
Study: 1771968

Group type: EXPERIMENTAL
Intervention: Inactivated and purified rabies viruses (IPRV) from Pittman Moore (PM) or Pasteur Virus (PV) strains
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inactivated and purified rabies viruses (IPRV) from European Bat Lyssavirus (EBL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inactivated and purified rabies viruses (IPRV) from Mokola (Mok) rabies-related virus strains
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ribonucleoprotein (RNP) from PV viruses
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ribonucleoprotein (RNP) from EBL viruses
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ribonucleoprotein (RNP) from Mok viruses
Number of subjects: 35
Study: 6749996

Group type: EXPERIMENTAL
Intervention: Propidium iodide (PI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diamidinophenylindol (DAPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethidium bromide (EB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EB-FITC combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PI-FITC combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAPI-TRITC combination
Number of subjects: 0
Study: 28139973

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Affected-limb-position
Number of subjects: 191

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 191

Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 191

Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 191
Study: 29986268

Group type: EXPERIMENTAL
Intervention: Varenicline adherence measured by salivary varenicline levels
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Normal metabolizers (NMR≥0.31)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Pill counts (self-reported adherence)
Number of subjects: 376
Study: 28427456

Group type: EXPERIMENTAL
Intervention: Surgery with atrial natriuretic peptide (ANP) administration for 3 days during the perioperative period
Number of subjects: 500

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 500
Study: 25300791

Group type: EXPERIMENTAL
Intervention: EP‐RDP
Number of subjects: 54

Group type: COMPARATOR
Intervention: C‐RDP
Number of subjects: 54
Study: 24125415

Group type: EXPERIMENTAL
Intervention: Beetroot juice (140 mL providing approximately 500 mg dietary nitrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 20
Study: 21912118

Group type: EXPERIMENTAL
Intervention: Gemcitabine and carboplatin (CG1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (CG8)
Number of subjects: 0
Study: 18981948

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 23
Study: 17012004

Group type: EXPERIMENTAL
Intervention: Class 2 elastic compression hosiery
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Class 3 elastic compression hosiery
Number of subjects: 300
Study: 14613435

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) as maintenance treatment for persistent asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of a long-acting inhaled beta2-agonist or a leukotriene modifier to ICS therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective measures of pulmonary function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asthma severity assessment
Number of subjects: 0
Study: 11106715

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 microg subcutaneously once per week for 48 weeks)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Interferon alfa-2a (6 million units subcutaneously three times per week for 12 weeks, followed by 3 million units three times per week for 36 weeks)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 531

Group type: COMPARATOR
Intervention: Interferon alfa-2a
Number of subjects: 531
Study: 9296405

Group type: EXPERIMENTAL
Intervention: Perphenazine 70 microg/kg
Number of subjects: 226

Group type: COMPARATOR
Intervention: Dexamethasone 150 microg/kg
Number of subjects: 226
Study: 27719743

Group type: EXPERIMENTAL
Intervention: 400 mg LCZ696 after low-fat meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg LCZ696 after high-fat meal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg LCZ696 under fasting condition
Number of subjects: 36
Study: 3943691

Group type: EXPERIMENTAL
Intervention: Visible vessels
Number of subjects: 129

Group type: COMPARATOR
Intervention: Other stigmata of recent hemorrhage
Number of subjects: 129

Group type: COMPARATOR
Intervention: No stigmata of recent hemorrhage
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Urgent partial gastrectomy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Pathological changes in bleeding artery
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ulcer penetration
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Mean external diameter of bleeding artery
Number of subjects: 129
Study: 29847828

Group type: EXPERIMENTAL
Intervention: Adapted physical activity for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study: 27041256

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted transversus abdominis plane (TAP) block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wound infiltration (INF)
Number of subjects: 80
Study: 24978674

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (im testosterone undecanoate) for 40 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo for 40 weeks
Number of subjects: 88
Study: 23484301

Group type: EXPERIMENTAL
Intervention: Glass fiber post and composite resin core
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pure titanium casting post and core
Number of subjects: 135

Group type: COMPARATOR
Intervention: No treatment (direct restoration)
Number of subjects: 135
Study: 21699953

Group type: EXPERIMENTAL
Intervention: P. ginseng extract (2g/day) for 4 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: P. ginseng extract (1g/day) for 4 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 82
Study: 18259825

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for pancreatic cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant therapy for pancreatic cancer
Number of subjects: 0
Study: 16649857

Group type: EXPERIMENTAL
Intervention: Diverse groups (racially heterogeneous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All-White groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whites in diverse groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to pretrial jury selection questions about racism
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exposure to pretrial jury selection questions about racism
Number of subjects: 0
Study: 14635236

Group type: COMPARATOR
Intervention: Women textile workers
Number of subjects: 267400
Study: 10959482

Group type: EXPERIMENTAL
Intervention: Lamivudine (100-150 mg daily)
Number of subjects: 41
Study: 8851242

Group type: EXPERIMENTAL
Intervention: Task group (counting longer tones)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-task group (no instructed task)
Number of subjects: 0
Study: 1284331

Group type: EXPERIMENTAL
Intervention: 150 micrograms levothyroxine per day (Group A)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 400 micrograms iodine per day (Group B)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 75 micrograms levothyroxine and 200 micrograms iodine per day (Group C)
Number of subjects: 166
Study: 2861759

Group type: EXPERIMENTAL
Intervention: Pancuronium (80 micrograms/kg iv)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pancuronium (80 micrograms/kg iv) in patients pretreated with beta-receptor blockers and receiving fentanyl (7 micrograms/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pancuronium (80 micrograms/kg iv) in patients not on preoperative beta-receptor blocker medication
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vecuronium (70 micrograms/kg iv)
Number of subjects: 16
Study: 31851172

Group type: EXPERIMENTAL
Intervention: Cortexin (10 days, once daily intramuscularly)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no pharmacotherapy)
Number of subjects: 54
Study: 29464980

Group type: EXPERIMENTAL
Intervention: TCA 33%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 90
Study: 26988134

Group type: EXPERIMENTAL
Intervention: Acceptance intervention
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Neutral comparison condition
Number of subjects: 66
Study: 25026806

Group type: EXPERIMENTAL
Intervention: Adaptol (3 tablets, 1500 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard treatment (disintoxication therapy, prednisolone 30‐60 mg/day, antihistamines, phototherapy, topical steroids, topical emollients)
Number of subjects: 80
Study: 22494062

Group type: EXPERIMENTAL
Intervention: I-gel(TM) laryngeal mask airway with sevoflurane
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: I-gel(TM) laryngeal mask airway with desflurane
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (preoperative measurement)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Comparison between sevoflurane and desflurane groups
Number of subjects: 47
Study: 21038653

Group type: EXPERIMENTAL
Intervention: BAI with oleum fructus bruceae (OFB) + chemotherapeutic agents (CTA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: BAI with chemotherapeutic agents (CTA) alone
Number of subjects: 103
Study: 17925417

Group type: EXPERIMENTAL
Intervention: One-legged exercise training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Two-legged exercise training
Number of subjects: 18
Study: 16398771

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg) and intravenous oxytocin (10 IU/hour)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 12924516

Group type: EXPERIMENTAL
Intervention: AutoSet (Resmed)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SOMNOsmart (Weinmann)
Number of subjects: 50
Study: 11076823

Group type: EXPERIMENTAL
Intervention: ICUS-guided provisional stenting
Number of subjects: 291

Group type: COMPARATOR
Intervention: Standard angiographic guidance
Number of subjects: 291
Study: 8794822

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg QD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol (95 mg QD)
Number of subjects: 20
Study: 1310464

Group type: EXPERIMENTAL
Intervention: Pipecuronium 60 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pipecuronium 80 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pipecuronium 100 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine (in Groups B and C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine and edrophonium (in Subgroup A)
Number of subjects: 60
Study: 6391153

Group type: EXPERIMENTAL
Intervention: 200 mg SAMe per os tid during oral contraceptive treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral contraceptives containing 50 micrograms ethynylestradiol plus 250 micrograms d-norgestrel
Number of subjects: 6
Study: 31079201

Group type: EXPERIMENTAL
Intervention: Three consecutive exercise days (3CON)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single bout of exercise (SB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Three alternate exercise days (3ALT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No exercise control (R)
Number of subjects: 10
Study: 29354952

Group type: EXPERIMENTAL
Intervention: Autologous blood injection at Zusanli (ST 36)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% NaCl at Zusanli (ST 36)
Number of subjects: 60
Study: 25250670

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23424017

Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone
Number of subjects: 862

Group type: COMPARATOR
Intervention: Control
Number of subjects: 862
Study: 21570271

Group type: EXPERIMENTAL
Intervention: 9 g brewer's yeast (42 μg Cr) daily for 3 months
Number of subjects: 40
Study: 19634546

Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg 15 minutes before induction
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo 15 minutes before induction
Number of subjects: 113
Study: 16557601

Group type: EXPERIMENTAL
Intervention: Transulnar approach
Number of subjects: 431

Group type: COMPARATOR
Intervention: Transradial approach
Number of subjects: 431
Study: 14960109

Group type: EXPERIMENTAL
Intervention: Sensorized thumb with piezoresistive force sensors
Number of subjects: 7
Study: 10856732

Group type: EXPERIMENTAL
Intervention: eprosartan (540+/‐96 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 8612032

Group type: EXPERIMENTAL
Intervention: Back school course
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 494
Study: 1588148

Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine
Number of subjects: 58000

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine (polysaccharide conjugated to diphtheria toxoid)
Number of subjects: 58000

Group type: COMPARATOR
Intervention: PRP-D vaccine
Number of subjects: 58000

Group type: COMPARATOR
Intervention: HbOC vaccine (oligosaccharide conjugated to CRM197 protein)
Number of subjects: 58000
Study: 6748780

Group type: EXPERIMENTAL
Intervention: Physician interview
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient interview
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Videotaped observation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chart audit
Number of subjects: 30
Study: 29027352

Group type: EXPERIMENTAL
Intervention: Spontaneous donor hypothermia (core body temperature <36°C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donor dopamine treatment
Number of subjects: 0
Study: 25702786

Group type: EXPERIMENTAL
Intervention: 20,000 IU of vitamin D3 per week
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study: 24737923

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory therapy after surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: No anti-inflammatory therapy after surgery
Number of subjects: 38
Study: 24417929

Group type: EXPERIMENTAL
Intervention: Aspirin group (continued aspirin, discontinued clopidogrel at least 5 days before surgery)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel group (had both until 3 days before surgery)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (discontinued antiplatelet therapy 5 days before surgery)
Number of subjects: 480
Study: 20497899

Group type: EXPERIMENTAL
Intervention: Institutionalized children
Number of subjects: 117

Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 117
Study: 18179713

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day) for bipolar mania
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day) for schizophrenia
Number of subjects: 406
Study: 16794788

Group type: EXPERIMENTAL
Intervention: Carvedilol (5 mg twice per day, increased to maximum tolerated dose)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Metoprolol tartrate (20 mg three times per day, increased to maximum tolerated dose)
Number of subjects: 650